Literature DB >> 7563309

High expression of a CD38-like molecule in normal prostatic epithelium and its differential loss in benign and malignant disease.

G Kramer1, G Steiner, D Födinger, E Fiebiger, C Rappersberger, S Binder, J Hofbauer, M Marberger.   

Abstract

PURPOSE: We characterize an undescribed antigen on prostatic epithelial cells, which is recognized by anti-CD38.
MATERIALS AND METHODS: Normal (3 cases), benign hyperplastic (10) and carcinomatous (10) prostatic tissues were analyzed using immunohistochemistry, immuno-electron microscopy and the Western blot test.
RESULTS: Comparison of prostatic and lymphatic CD38 antigen revealed identical bands at 45 kD. Electron microscopy demonstrated anti-CD38 reactivity on the cytoplasmic membrane and within the secretory vacuoles. Double labeling with anti-cytokeratin types 5/15 and 8/18 confirmed that basal and secretory normal prostatic epithelial cells express CD38. By contrast, a complete loss was found in malignant (52.8%), tumor-surrounding nonmalignant (16.3%) and benign prostatic hyperplasia derived glands (3.7%).
CONCLUSIONS: CD38 is a novel prostatic antigen. Its role in intracellular calcium mobilization may contribute to smooth muscle cell contraction and/or sperm motility.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7563309

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  16 in total

1.  Characterization of prostate cell types by CD cell surface molecules.

Authors:  Alvin Y Liu; Lawrence D True
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

2.  Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors.

Authors:  Claudia C S Chini; Anatilde M Gonzalez Guerrico; Veronica Nin; Juliana Camacho-Pereira; Carlos Escande; Maria Thereza Barbosa; Eduardo N Chini
Journal:  Clin Cancer Res       Date:  2013-09-11       Impact factor: 12.531

3.  [Chronic inflammation as promotor and treatment target in benign prostate hyperplasia (BPH) and in prostate cancer].

Authors:  G Kramer; D Mitteregger; A Maj-Hes; S Sevchenco; W Brozek
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

4.  Human CD38 is an authentic NAD(P)+ glycohydrolase.

Authors:  V Berthelier; J M Tixier; H Muller-Steffner; F Schuber; P Deterre
Journal:  Biochem J       Date:  1998-03-15       Impact factor: 3.857

5.  Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile.

Authors:  Alvin Y Liu; Martine P Roudier; Lawrence D True
Journal:  Am J Pathol       Date:  2004-11       Impact factor: 4.307

Review 6.  CD38 autoimmunity: recent advances and relevance to human diabetes.

Authors:  A Antonelli; E Ferrannini
Journal:  J Endocrinol Invest       Date:  2004 Jul-Aug       Impact factor: 4.256

7.  Seminal CD38 is a pivotal regulator for fetomaternal tolerance.

Authors:  Byung-Ju Kim; Yun-Min Choi; So-Young Rah; Dae-Ryoung Park; Seon-Ah Park; Yun-Jo Chung; Seung-Moon Park; Jong Kwan Park; Kyu Yun Jang; Uh-Hyun Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-15       Impact factor: 11.205

8.  CD38 Inhibits Prostate Cancer Metabolism and Proliferation by Reducing Cellular NAD+ Pools.

Authors:  Jeffrey P Chmielewski; Sarah C Bowlby; Frances B Wheeler; Lihong Shi; Guangchao Sui; Amanda L Davis; Timothy D Howard; Ralph B D'Agostino; Lance D Miller; S Joseph Sirintrapun; Scott D Cramer; Steven J Kridel
Journal:  Mol Cancer Res       Date:  2018-08-03       Impact factor: 5.852

Review 9.  Prostate Luminal Progenitor Cells in Development and Cancer.

Authors:  Dingxiao Zhang; Shuhong Zhao; Xinyun Li; Jason S Kirk; Dean G Tang
Journal:  Trends Cancer       Date:  2018-10-01

10.  In silico dissection of cell-type-associated patterns of gene expression in prostate cancer.

Authors:  Robert O Stuart; William Wachsman; Charles C Berry; Jessica Wang-Rodriguez; Linda Wasserman; Igor Klacansky; Dan Masys; Karen Arden; Steven Goodison; Michael McClelland; Yipeng Wang; Anne Sawyers; Iveta Kalcheva; David Tarin; Dan Mercola
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.